Skip to content

Valbenazine

VMAT2 inhibitor • Last reviewed 2025-09-23

Brands: Ingrezza

Sources updated 2025 • 1 references

Summary

General Information

Indicated for: INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with: - tardive dyskinesia. ( 1 ) - chorea associated with Huntington’s disease. ( 1 ) VMAT2 inhibitor

Dosage & Administration

Typical dose range: 40–80 mg/day

Indications (label)

INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with: - tardive dyskinesia. ( 1 ) - chorea associated with Huntington’s disease. ( 1 )

View labelExact

Mechanism (brief)

Vesicular monoamine transporter 2 (VMAT2) inhibitor.

Metabolism & Half‑life

  • Metabolism: CYP3A4, 2D6; active metabolite.
  • Half‑life: Long (hours).

Therapeutic Drug Monitoring (TDM)

Recommended: No

References